Inovio Pharmaceuticals (INO) Earnings Dates, Call Summary & Reports

5,993 Followers

Earnings Data

Report Date

Aug 12, 2026

TBA (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

-0.24

Last Year’s EPS

-0.61

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 2 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:May 13, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call conveyed substantial progress on multiple fronts—regulatory milestones (BLA accepted, mid-cycle review with no new issues, PDUFA date set), strong Phase I/II efficacy/safety signals, commercial preparation and advancing partnerships—tempered by material near-term financial constraints (cash declined ~36%, an $18M estimated Q2 burn and runway into only Q1 2027), outstanding regulatory questions about accelerated approval eligibility and an active competitive landscape. Overall the tone was optimistic about the program and platform advancement but realistic about financing and regulatory uncertainties.

Company Guidance

In the call management reiterated that the INO‑3107 BLA—accepted for FDA review under the accelerated approval pathway in December 2025—remains on track for an October 30, 2026 PDUFA target date, with the FDA completing the mid‑cycle review (no new significant issues), late‑cycle review slated for Q3 2026, and an informal meeting to discuss accelerated‑approval eligibility and feedback on the confirmatory‑trial protocol (already submitted to the IND) expected but not yet scheduled; operational guidance included Q1 2026 cash, cash equivalents and short‑term investments of $37.7M (down from $58.5M at 12/31/2025), ~ $16M net proceeds from an April 2026 public offering, an estimated operational net cash burn of ~$18M for Q2 2026 and a projected cash runway into Q1 2027 (exclusive of any future financings); reported results showed Q1 operating expenses of $21.9M (vs. $25.1M in Q1 2025, a 13% decrease) and a net loss of $19.7M, or $0.28 per share (vs. $19.7M, or $0.51 per share in Q1 2025); clinical/regulatory guidance highlighted Phase I/II data in which the majority of patients experienced a 50–100% reduction in surgeries in year 1 with continued improvement in year 2, a Phase I/II population that had 2–8 surgeries in the prior year (supporting an anticipated label similar to the approved product), and market context citing ~14,000 prevalent RRP patients (other estimates ~27,000) and competitor PAPZIMEOS metrics referenced at ~$21.6M with single‑digit penetration in year 1, underpinning Inovio’s plan to be a fast‑following commercial entrant.

Regulatory Progress on INO-3107

BLA for INO-3107 accepted for review under the FDA accelerated approval program (file accepted Dec 2025); PDUFA target date set for October 30, 2026. FDA completed mid-cycle review with no new significant issues and scheduled late-cycle review for Q3 2026. FDA reiterated intent to schedule an informal meeting to discuss accelerated approval eligibility.

Strong Phase I/II Clinical Efficacy and Safety Signals

Phase I/II results showed the vast majority of patients experienced a 50% to 100% reduction in surgeries in year 1 with continued clinical improvement in year 2. Safety profile highlighted as improved versus the comparator, notably not requiring surgery to maintain minimal residual disease during the dosing window.

Commercial Readiness and Product Differentiation

Company completed targeting, segmentation and product positioning; plans to commercialize in the U.S. with support from a contract sales organization and engaged logistics, specialty distributor, specialty pharmacy and patient hub partners. Key operational differentiation versus competitor: no ultra-cold chain and no requirement for surgery during dosing, and positive feedback from physicians and patient community at COSM.

Pipeline Partnerships and Platform Advances

Announced collaboration with Akeso and Dana-Farber to evaluate INO-5412 + dual checkpoint inhibitor in GBM (Phase II adaptive platform). Advanced DPROT platform with preclinical Factor VIII data for hemophilia A and added rare disease targets (Fabry disease, hypophosphatasia) to the pipeline; pursuing partners to accelerate development.

Balance Sheet Strengthened via Equity Offering

Completed underwritten public equity offering in April 2026 with net proceeds of approximately $16 million, extending estimated cash runway into Q1 2027 (beyond the PDUFA date). Cash, cash equivalents and short-term investments at March 31, 2026 were $37.7 million.

Operating Expense Reduction

Operating expenses decreased 13% year-over-year from $25.1 million in Q1 2025 to $21.9 million in Q1 2026, reflecting resource prioritization toward INO-3107.

Per-Share Loss Improved

Reported net loss of $19.7 million in Q1 2026 (same dollar loss as Q1 2025), with loss per share narrowing to $0.28 from $0.51 a year earlier (approximately a 45% improvement in loss per share, driven by share count changes).

Inovio Pharmaceuticals (INO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

INO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2026	2026 (Q2)	-0.24 / -	-0.61	―	―	―
May 13, 2026	2026 (Q1)	-0.35 / -0.28	-0.51	45.10% (+0.23)
Mar 12, 2026	2025 (Q4)	-0.36 / 0.06	-0.65	109.23% (+0.71)
Nov 10, 2025	2025 (Q3)	-0.42 / -0.87	-0.89	2.25% (+0.02)
Aug 12, 2025	2025 (Q2)	-0.61 / -0.61	-1.19	48.74% (+0.58)	―
May 13, 2025	2025 (Q1)	-0.69 / -0.51	-1.31	61.07% (+0.80)	―
Mar 18, 2025	2024 (Q4)	-0.84 / -0.65	-1.1	40.91% (+0.45)	―
Nov 14, 2024	2024 (Q3)	-1.15 / -0.89	-1.56	42.95% (+0.67)	―
Aug 08, 2024	2024 (Q2)	-1.10 / -1.19	-1.56	23.72% (+0.37)	―
May 13, 2024	2024 (Q1)	-1.01 / -1.31	-1.92	31.77% (+0.61)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

INO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 13, 2026	$1.34	$1.36	+1.49%
Mar 12, 2026	$1.68	$1.66	-1.19%
Nov 10, 2025	$2.15	$2.00	-6.98%
Aug 12, 2025	$1.49	$1.70	+14.09%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.